On the Record · Vir Biotechnology

Vir Biotechnology acquisitions, on the record

The businesses Vir Biotechnology bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
TomegaVax, Inc. Word for word“For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018.” 10-K for 2023	acquisition	September 2016	—
Humabs BioMed SA Word for word“For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018.” 10-K for 2023	acquisition	August 2017	—
Agenovir Corporation Word for word“For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018.” 10-K for 2023	acquisition	January 2018	—
Statera Health, LLC Word for word“For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018.” 10-K for 2023	acquisition	February 2018	—
Humabs BioMed SA (Humabs) Word for word“Prior to our acquisition of Humabs BioMed SA (referred to herein as Humabs) in August 2017, the former parent company of Humabs (later consolidated into Humabs) entered into an exclusive license agreement in December 2011 with the Institute for Research in Biomedicine (IRB, and the agreement, the IRB Agreement).” 10-K for 2024	acquisition	August 2017	—
numerous biotechnology companies Word for word“For example, we acquired numerous biotechnology companies between 2016 and 2018.” 10-K for 2024	acquisition	between 2016 and 2018	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2017-12-31	$27.3 million

Deal filings since 2016

2026-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-02-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-12-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-09-10 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2024-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-02-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-11-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-10-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-06-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-05-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-05-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-02-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-12-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-11-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Vir Biotechnology’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-23. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.